Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Recent & Breaking News (TSXV:CLAS.H)

Kalytera Will Not Proceed with Vote on Potential Share Consolidation

GlobeNewswire July 26, 2019

Kalytera Announces Completion of Food Effect and QTc Study

GlobeNewswire July 16, 2019

Kalytera to Hold Annual and Special Meeting on July 29, 2019

GlobeNewswire July 5, 2019

Kalytera to Acquire CBD Extraction Business

GlobeNewswire June 27, 2019

Kalytera Provides Update on GVHD Program

GlobeNewswire June 25, 2019

Kalytera Announces Grant of Stock Options to Directors

GlobeNewswire June 21, 2019

Kalytera Announces Changes to Board of Directors

GlobeNewswire June 21, 2019

Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

GlobeNewswire June 18, 2019

Kalytera Reports First Quarter 2019 Financial Results

GlobeNewswire May 31, 2019

Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office

GlobeNewswire May 29, 2019

Kalytera Announces Data Further Elucidating CBD's Mechanisms of Action in Prevention of GVHD

GlobeNewswire May 28, 2019

Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

GlobeNewswire May 21, 2019

Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering

GlobeNewswire May 14, 2019

Kalytera Reports 2018 Financial Results

GlobeNewswire May 1, 2019

Kalytera Therapeutics, Inc. Announces Closing of Public Offering

GlobeNewswire April 26, 2019

IIROC Trading Resumption - KALY

Canada NewsWire April 17, 2019

Kalytera Therapeutics Announces Filing of Short Form Prospectus

GlobeNewswire April 17, 2019

IIROC Trading Halt - KALY

Canada NewsWire April 17, 2019

Kalytera Therapeutics Announces Short Form Prospectus Offering of Units

GlobeNewswire April 3, 2019

Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

GlobeNewswire March 22, 2019